share_log

SIGA Technologies | 10-Q: Q2 2024 Earnings Report

SIGA Technologies | 10-Q: Q2 2024 Earnings Report

SIGA Technologies | 10-Q：2024财年二季报
美股SEC公告 ·  2024/08/01 17:01

Moomoo AI 已提取核心信息

SIGA Technologies reported Q2 2024 revenues of $21.8 million, with product sales reaching $20.7 million, primarily driven by $17.6 million in IV TPOXX sales to the U.S. Government and $3.0 million in international oral TPOXX sales. The company recorded net income of $1.8 million, or $0.03 per share, compared to a net loss of $2.9 million in Q2 2023.Operating expenses totaled $20.7 million, including $12.3 million in cost of sales and $5.5 million in selling, general and administrative expenses. Research and development expenses decreased to $2.9 million from $5.1 million in the prior year quarter, primarily due to reduced activities under the PEP Label Expansion R&D Contract.The company maintained a strong financial position with $106.9 million in cash and cash equivalents as of June 30, 2024. Notably, BARDA exercised a $112.5 million option for oral TPOXX procurement in July 2024, increasing cumulative exercised options to $519.6 million under the 19C BARDA Contract.
SIGA Technologies reported Q2 2024 revenues of $21.8 million, with product sales reaching $20.7 million, primarily driven by $17.6 million in IV TPOXX sales to the U.S. Government and $3.0 million in international oral TPOXX sales. The company recorded net income of $1.8 million, or $0.03 per share, compared to a net loss of $2.9 million in Q2 2023.Operating expenses totaled $20.7 million, including $12.3 million in cost of sales and $5.5 million in selling, general and administrative expenses. Research and development expenses decreased to $2.9 million from $5.1 million in the prior year quarter, primarily due to reduced activities under the PEP Label Expansion R&D Contract.The company maintained a strong financial position with $106.9 million in cash and cash equivalents as of June 30, 2024. Notably, BARDA exercised a $112.5 million option for oral TPOXX procurement in July 2024, increasing cumulative exercised options to $519.6 million under the 19C BARDA Contract.
SIGA Technologies报告2024年第二季度收入为2180万美元，产品销售达到2070万美元，主要得益于向美国政府销售的1760万美元IV TPOXX和300万美元的国际口服TPOXX销售。该公司记录的净利润为180万美元，或每股0.03美元，较2023年第二季度的净亏损290万美元有所改善。营业费用总计为2070万美元，包括1230万美元的销售成本和550万美元的销售、一般和行政费用。研发费用从上年同期的510万美元降至290万美元，主要是由于PEP标签扩展研发合同下的活动减少。截至2024年6月30日，该公司维持了强劲的财务状况，现金及现金等价物为10690万美元。值得注意的是，BARDA于2024年7月行使了一项价值11250万美元的口服TPOXX采购期权，使19C BARDA合同项下的累计已行使期权增加至51960万美元。
SIGA Technologies报告2024年第二季度收入为2180万美元，产品销售达到2070万美元，主要得益于向美国政府销售的1760万美元IV TPOXX和300万美元的国际口服TPOXX销售。该公司记录的净利润为180万美元，或每股0.03美元，较2023年第二季度的净亏损290万美元有所改善。营业费用总计为2070万美元，包括1230万美元的销售成本和550万美元的销售、一般和行政费用。研发费用从上年同期的510万美元降至290万美元，主要是由于PEP标签扩展研发合同下的活动减少。截至2024年6月30日，该公司维持了强劲的财务状况，现金及现金等价物为10690万美元。值得注意的是，BARDA于2024年7月行使了一项价值11250万美元的口服TPOXX采购期权，使19C BARDA合同项下的累计已行使期权增加至51960万美元。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

独立文件6  查看翻译

独立文件7  查看翻译

独立文件8  查看翻译

独立文件9  查看翻译

独立文件10  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间